Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.99Last Year’s EPS
0.45Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -6.10%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant commercial success with record-breaking revenue growth and successful product launches. The company is in a strong financial position and advancing its pipeline with promising data presentations. However, there were challenges related to seasonality, gross-to-net impacts, and unique market dynamics in CIDP that affected growth. Overall, the sentiment is positive due to the strong growth and strategic advancements outweighing the lowlights.Company Guidance
During the call, Argenx provided detailed guidance on its strategic vision and financial performance. The company emphasized its Vision 2030, targeting 50,000 patients across 10 labeled indications and advancing five Phase III assets. In the first quarter of fiscal year 2025, Argenx reported total operating income of $807 million, with $790 million from product net sales, marking a 99% year-over-year growth. The product net sales were distributed as $681 million in the U.S., $32 million in Japan, $57 million in the rest of the world, and $20 million from product supply to Zai Lab in China. The company also highlighted the successful launch of VYVGART Hytrulo pre-filled syringe in the U.S. and Germany, with an optimal FDA label approval expected to drive further expansion in gMG and CIDP markets. Argenx maintained a gross margin of 90% in Q1 2025, and total operating expenses were $668 million, resulting in an operating profit of $139 million. The company's effective tax rate was 16%, with a quarterly net profit of $169 million. Argenx ended the quarter with a cash balance of $3.6 billion, an increase of $238 million from Q4 2024, primarily driven by cash flow from operations.Record-Breaking Revenue and Growth
Total operating income in the first quarter of 2025 was $807 million, with $790 million in product net sales, representing 99% growth compared to the prior year quarter.
Successful Product Launch
Launched the VYVGART Hytrulo pre-filled syringe for self-injection in the U.S. and Germany, enhancing patient access and convenience.
Strong Financial Position
Increased cash balance to $3.6 billion at quarter end, driven by cash flow from operations, providing the company with a strong financial foundation.
Significant Pipeline Progress
Advancing 10 registrational and 10 proof-of-concept studies, with multiple readouts expected across the pipeline, including Phase III for seronegative gMG.
Positive Data Presentation
Presented data at AAN reinforcing the potential of VYVGART, with 56.5% of patients achieving minimal symptom expression at any point during treatment.
ARGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $622.93 | $569.12 | -8.64% |
Feb 27, 2025 | $623.02 | $624.70 | +0.27% |
Oct 31, 2024 | $551.71 | $586.30 | +6.27% |
Jul 25, 2024 | $464.36 | $486.33 | +4.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Argenx Se (ARGX) report earnings?
Argenx Se (ARGX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Argenx Se (ARGX) earnings time?
Argenx Se (ARGX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARGX EPS forecast?
ARGX EPS forecast for the fiscal quarter 2025 (Q2) is 2.99.